



### **AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer**

CAMBRIDGE, Mass. – May 15, 2017 – The Board of Directors of AVEO Oncology (NASDAQ: AVEO) today issued the following statement regarding the passing of its Lead Director Henri A. Termeer.

“We are deeply saddened at the loss of a visionary, mentor, colleague and dear friend, Henri A. Termeer. Henri’s wisdom, foresight and persistence fundamentally changed our industry, which exists to serve patients suffering from devastating diseases. His passion for taking on the biggest challenges in medicine has made, and continues to make, a tremendous difference for so many. He has been a role model and an inspiration for countless others to do the same. We are privileged to have worked with Henri to pursue his vision. Our thoughts are with his family.”

#### **About AVEO**

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). For more information, please visit the company’s website at [www.aveooncology.com](http://www.aveooncology.com).

AVEO Contact:  
David Pitts, Argot Partners  
(212) 600-1902  
[aveo@argotpartners.com](mailto:aveo@argotpartners.com)